Literature DB >> 25412784

An update on topical therapies for mild-moderate psoriasis.

Peter C M van de Kerkhof1.   

Abstract

Topical therapies are the mainstream treatment of psoriasis because most patients have mild disease. First-line treatments are vitamin D derivatives and corticosteroids. These treatments are usually given in combination schedules. For topical treatments the selection of the most appropriate vehicle is of major importance, thus improving adherence to the treatment, which frequently is impaired by the complexities of topical therapeutic choices. Evidence for efficacy and safety of topical treatments is readily available for vitamin D treatments and short-term treatment with corticosteroids. However, the scientific evidence for longer-term treatments is limited. Multiple new small molecules are in various stages of development and are reviewed.

Entities:  

Keywords:  Calcipotriol; Calcitriol; Corticosteroids; Ditranol; Small molecules; Tar; Tazarotene

Mesh:

Substances:

Year:  2015        PMID: 25412784     DOI: 10.1016/j.det.2014.09.006

Source DB:  PubMed          Journal:  Dermatol Clin        ISSN: 0733-8635            Impact factor:   3.478


  9 in total

Review 1.  Annoying Psoriasis and Atopic Dermatitis: A Narrative Review.

Authors:  Wei-Yu Chen; Shao-Chuan Chen; Shou-Yi Hsu; Yu-An Lin; Chun-Ming Shih; Chun-Yao Huang; Kuo-Hsien Wang; Ai-Wei Lee
Journal:  Int J Mol Sci       Date:  2022-04-28       Impact factor: 6.208

Review 2.  Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.

Authors:  Paolo Gisondi; Giampiero Girolomoni
Journal:  Drug Des Devel Ther       Date:  2016-05-25       Impact factor: 4.162

3.  Bioactive Dietary VDR Ligands Regulate Genes Encoding Biomarkers of Skin Repair That Are Associated with Risk for Psoriasis.

Authors:  Amitis Karrys; Islam Rady; Roxane-Cherille N Chamcheu; Marya S Sabir; Sanchita Mallick; Jean Christopher Chamcheu; Peter W Jurutka; Mark R Haussler; G Kerr Whitfield
Journal:  Nutrients       Date:  2018-02-04       Impact factor: 5.717

4.  JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.

Authors:  Ana Karina Alves de Medeiros; Reinhart Speeckaert; Eline Desmet; Mireille Van Gele; Sofie De Schepper; Jo Lambert
Journal:  PLoS One       Date:  2016-10-06       Impact factor: 3.240

Review 5.  Role of betamethasone valerate 2.250 mg medicated plaster in the treatment of psoriasis and other dermatological pathologies: a review.

Authors:  Sandra Ly; Jean Michel Amici
Journal:  Drugs Context       Date:  2018-08-20

Review 6.  Apoptotic or Antiproliferative Activity of Natural Products against Keratinocytes for the Treatment of Psoriasis.

Authors:  Tse-Hung Huang; Chwan-Fwu Lin; Ahmed Alalaiwe; Shih-Chun Yang; Jia-You Fang
Journal:  Int J Mol Sci       Date:  2019-05-24       Impact factor: 6.208

Review 7.  Update on psoriasis immunopathogenesis and targeted immunotherapy.

Authors:  Satveer K Mahil; Francesca Capon; Jonathan N Barker
Journal:  Semin Immunopathol       Date:  2015-11-16       Impact factor: 9.623

8.  Dithranol targets keratinocytes, their crosstalk with neutrophils and inhibits the IL-36 inflammatory loop in psoriasis.

Authors:  Theresa Benezeder; Clemens Painsi; VijayKumar Patra; Saptaswa Dey; Martin Holcmann; Bernhard Lange-Asschenfeldt; Maria Sibilia; Peter Wolf
Journal:  Elife       Date:  2020-06-02       Impact factor: 8.140

Review 9.  Clinical and Genetic Heterogeneity of CARD14 Mutations in Psoriatic Skin Disease.

Authors:  Laura Israel; Mark Mellett
Journal:  Front Immunol       Date:  2018-10-16       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.